Keywords: Liver, Contrast Agent, NAFLD,NASH, Gd-DPTA-EOB, Pharmacokinetic ModelingDue to the increased global prevalence of non-alcoholic fatty liver disease (NAFLD), there is a significant need for precise and non-invasive clinical methods to detect early stages of non-alcoholic steatohepatitis (NASH), which can progress to cirrhosis. We investigate the possibility of using the hepatocyte specific contrast agent Gd-EOB-DPTA based DCE-MRI in combination with mathematical modelling to assess hepatobiliary influx, as a possible biomarker for early NASH detection. We show a tentative correlation between increased portal inflammation and decreased hepatic Gd-EOB-DPTA uptake in a cohort of prospectively included patients with suspected chronic liver disease.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords